Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

Conatus Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on liver disease and cancer, closed a $7.5M financing bring the total Series B round to $32.5M. Participants include MPM Capital.

Conatus Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on hepatic disease and oncology, closed a $20M Series B financing. Participants include AgeChem Venture Fund, Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners and Roche Venture Fund.

Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.

Cytheris (France) a clinical-stage biopharmaceutical immune modulation company focused on HIV, HCV and oncology, closed a $14.3M Series D financing. Participants include CDC Entreprises, Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity and Forbion Capital Partners.

AiCuris (Germany) a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria, closed a $74.8M Series B financing. Participants include Santo Holding and Bayer Healthcare.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK […]

Presidio Pharmaceuticals (San Francisco, CA) a preclinical-stage specialty pharmaceutical company focused on HIV and HCV, closed a $27M Series B, bringing the total round financing to $53M. Participants include New Leaf Venture Partners, Panorama Capital, Baker Brothers Investments, Ventures West Capital, Bay City Capital, Nexus Medical Partners and Sagamore BioVentures.

Biolex Therapeutics (Pittsboro, NC) clinical-stage biopharmaceutical company developing therapeutic proteins and monoclonal antibodies for hepatitis C, closed a $60M Series D financing. Participants include Clarus Ventures, OrbiMed Advisors, Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corp, Investor Growth Capital, Polaris Ventures, Mitsui & Company, The Dow Chemical Company, JP Morgan Securities and North Carolina […]

Phenomix (San Diego, Calif.) a drug discovery and development company focused on the treatment of Type 2 diabetes and hepatitis C raised a $55M Series C financing. The deal was led by Nomura Phase4 and joined by JPMorgan, Delphi Ventures, Baker Brothers, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and […]

  Intarcia Therapeutics (Emeryville, CA) a biopharmaceutical company developing therapies for Type 2 Diabetes and Hepatitis C raised $50M in a Series BB Financing. The round was led by New Leaf Venture, and joined by Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, and Granite Global Ventures.

  

to top of page...